Company

Location

Amt. (M)

Details

Date

TOTAL: $1,221M

Aduro Biotech Inc.

Berkeley, Calif.

$51.4

Aduro raised $51.4M in a series D preferred stock financing; investors were Orbimed, Janus Capital Management LLC, funds managed by Franklin Advisers Inc., Jennison Associates LLC (on behalf of clients), Foresite Capital Management LLC, private investment funds advised by Clough Capital Partners LP, and other health care investors; the Morningside group and some of the company's existing investors also participated in the financing; Leerink Partners LLC acted as placement agent

1/6/15

Amerigen Pharmaceuticals Ltd.

Lyndhurst, N.J.

$35

An affiliate of Shanghai Fosun Pharmaceutical Group Ltd. agreed to invest $35M in Amerigen in the form of newly issued equity

1/12/15

Autolus Ltd.

London

$45.6

Autolus Ltd. launched a $45.6M series A round from Syncona LLP

1/23/15

Blend Therapeutics Inc.

Watertown, Mass.

$21

Blend secured $21M in new funding in an expansion of its series B round, as well as debt financing from an institutional investment firm

1/8/15

Clementia Pharmaceuticals Inc.

Montreal

$10

Secured an additional $10M from its current investors led by Orbimed Advisors with participation by BDC Venture Capital; the new funds bring the total amount raised in a series A financing round to $32.5M, following the first closing in January 2014 of $22.5M

1/6/15

Colucid Pharmaceuticals Inc.

Durham, N.C.

$37.1

Colucid completed a $37.1M series C preferred stock offering led by TVM Capital Life Science, and including participation from Novo Ventures and Auriga Partners, as well as existing investors Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures

1/14/15

Cristal Therapeutics BV

Maastricht, the Netherlands

$7.5

Cristal raised $7.5M in a series A round; backers include Chemelot Ventures, Thuja Capital, Biogeneration Ventures, Nedermass, Utrecht University Holding and Beheer Innovativefonds Provincie Limburg

1/2/15

Cytomx Therapeutics Inc.

South San Francisco

$20

Cytomx raised $20M in a series C financing round led by Pfizer Venture Investments, with participation from existing investors Third Rock Ventures, Canaan Partners and the Roche Venture Fund

1/7/15

Effrx Pharmaceuticals SA

Freienbach, Switzerland

$2.3

Effrx Pharmaceuticals received $2.3M in an equity round

1/13/15

Engene Inc.

Vancouver, British Columbia

$10.85

Forbion Capital Partners led the closing of a C$13.5M (US$10.85M) series B financing round for Engene, with a syndicate of life science investors including existing shareholder, Merck Lumira Biosciences Fund, and new investors, Fonds de Solidarité FTQ and Inbio Ventures (Luxembourg)

1/26/15

Engeneic Ltd.

Sydney

$10

Completed an oversubscribed $10M series B financing round led by new investor GRT Capital Partners LLC and including participation from other new U.S. and existing investors, as well as Foley Ventures LLC and various partners of Foley & Lardner LLP

1/7/15

Genenta Science SpA

Milan

$7

Genenta raised $7M in a first closing of its series A round

1/26/15

Genkyotex SA

Geneva

$20

Genkyotex raised $20M in a series D round led by Neomed Management and including VI Partners and Biomedinvest, Edmond de Rothschild Investment Partners, Eclosion2 and Vesalius Biocapital Partners

1/8/15

Global Blood Therapeutics Inc.

South San Francisco

$48

Closed a $48M series B financing from Wellington Management Company LLP, RA Capital, Deerfield Management, Sabby Capital, Perceptive Life Sciences, an affiliate of Cowen Group and one undisclosed blue chip public investment fund

1/7/15

Hua Medicine Ltd.

Shanghai

$25

Hua raised $25M through a series B round from Frontline Bioventures and TF Capital, as well as all series A investors, Arch, Venrock, Fidelity, Wuxi Ventures and SAIL; it was led by Ally Bridge Group

1/15/15

Innovent Biologics Inc.

Shanghai

$97

Innovent raised ¥600M (US$97M) in a series C round led by new investor Legend Capital, Temasek and two more undisclosed backers, and including follow-on investors, Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures and Frontline Bioventures

1/23/15

Maat Pharma

France

$1.25

Seventure Partners, of Paris, invested €1M (US$1.25M) in Maat Pharma, and has committed a further €1M investment on achievement of scientific milestones

1/12/15

Moderna Therapeutics Inc.

Cambridge, Mass.

$450

Moderna raised $450M in one of the largest venture capital financings for biotech; new investors participating in the financing round were Viking Global Investors LP, Invus, RA Capital Management, and Wellington Management Co. LLP, as well as existing investors Astrazeneca plc and Alexion Pharmaceuticals Inc.

1/6/15

Neurophage Pharmaceuticals Inc.

Cambridge, Mass.

$10

Neurophage raised $10M in a series D private equity financing from new investors, bringing the total round to $27M; $17M was raised in March 2014

1/15/15

Novabiotics

Aberdeen, UK

$7.6

Novabiotics said Woodford Investment Management LLP has invested £5M (US$7.6M) in a private placement

1/21/15

Novocure Inc.

St. Helier, Jersey Isle

$25

Novocure entered a term loan agreement with an investment fund managed by Pharmakon Advisors LP and will receive $25M at closing; up to $75M of additional funding will be available to the company, at its option, through June 30, 2016

1/9/15

Puretech

Boston

$50

Puretech closed a $50M growth stage investment round from existing investors

1/12/15

Regenxbio Inc.

Washington

$30

Regenxbio completed a $30M series C financing round led by Venrock and Brookside Capital with participation from Deerfield Management and an unnamed new investor; existing investors, Foxkiser and Fidelity Biosciences, also participated

1/22/15

Retrosense Therapeutics Inc.

Ann Arbor, Mich.

$6

Retrosense secured $6M in a series A financing from Nerveda, Blue Water Angels, SDL Ventures, Tech Coast Angels and Michigan Economic Development Corp.

1/9/15

Seres Health Inc.

Cambridge, Mass.

$65

Seres Health completed a $65M series D preferred stock investment by Nestlé Health Science

1/12/15

Solvanix Pty Ltd.

Sydney

$1.64

Solvanix was launched with start-up financing from Australia's Medical Research Commercialisation Fund (MRCF), which committed A$2M (US$1.64M)

1/16/15

Steadymed Ltd.

San Ramon, Calif.

$12.2

Steadymed secured $12.2M in an equity financing that was co-led by funds advised by subsidiaries of Federated Investors Inc. and Deerfield Management Co. LP, the company's largest existing shareholders, which also participated; Wells Fargo Securities acted as sole placement agent on the transaction

1/30/15

Surface Oncology Inc.

Cambridge, Mass.

$35

Surface Oncology closed a $35M series A investment round led by Atlas Venture, Fidelity Biosciences, Lilly Ventures and New Enterprise Associates; Amgen Ventures, Novartis Institute for Biomedical Research and Elliott Sigal, former head of R&D at Bristol-Myers Squibb Co., also joined the financing

1/9/15

Symic Biomedical Inc.

San Francisco

$15

Symic raised $15M in a series A round led by Lilly Ventures, and including Den Danske Forskingsfond, Mitsui Global Investment, Ally Bridge Group and Incube Ventures

1/5/15

Trevi Therapeutics Inc.

New Haven, Conn.

$15

Trevi Therapeutics closed a $15M senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender

1/9/15

Ultimovacs AS

Oslo, Norway

$5.9

Ultimovacs carried out a NOK45M (US$5.9M) share issue with DNB Markets and Arctic Securities as financial advisors

1/23/15

Vaxart Inc.

South San Francisco

$18.4

Vaxart raised $18.4M through a convertible note financing led by Care Capital of Princeton, N.J.

1/9/15

Vtesse Inc.

Gaithersburg, Md.

$25

Vtesse raised $25M in a series A round from the syndicate of life sciences investors behind Cydan Development Inc.; the round was led by New Enterprise Associates and included Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments

1/8/15

Notes

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

This chart includes only biotech companies that develop therapeutics.

ND = Not disclosed.